Plaintiffs lawyers will argue that Novo Nordisk had an obligation to warn even if the drug only slightly increased the baseline risk, especially since patients with diabetes are already vulnerable to ocular damage and would be even more cautious if fully informed
Most people do well with 5/16 inch (8mm) needles for subcutaneous injection
Its an exciting moment after decades of unsuccessful attempts to find effective treatments for people living with obesity. - Juan Franco , co-lead researcher from Heinrich Heine University Dsseldorf, Germany
weight outcomes were modest and inconsistent, and development for obesity treatment was not continued
In chronic conditions like diabetes and obesity, where standard dosing may not be effective for all patients, off-label prescribing is common
No, it is not approved by the FDA or EMA and is considered a research chemical